Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Phase 2

Completed

Conditions: Progesterone Receptor-positive Breast Cancer
Estrogen Receptor-positive Breast Cancer
Oral Complications
Stage IIIB Breast Cancer
HER2-negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: mucoadhesive oral wound rinse
Other: laboratory biomarker analysis

First Posted Date: 2013-12-19

Last Posted Date: 2020-09-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 61

Registration Number: NCT02015559

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: degarelix
Drug: enzalutamide
Drug: trametinib
Drug: dasatinib

First Posted Date: 2013-11-21

Last Posted Date: 2024-10-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT01990196

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Phase 1

Completed

Conditions: Recurrent Prostate Cancer
Stage IIA Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Stage I Prostate Cancer

Interventions: Dietary Supplement: green tea extract
Other: placebo
Drug: quercetin
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2013-07-31

Last Posted Date: 2021-06-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 32

Registration Number: NCT01912820

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Veterans Administration Los Angeles Healthcare System, Los Angeles, California, United States

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

Early Phase 1

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: 68Ga-DOTATATE

First Posted Date: 2013-06-10

Last Posted Date: 2024-07-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT01873248

Locations: 🇺🇸
University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology, Los Angeles, California, United States

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Phase 2

Withdrawn

Conditions: Adenocarcinoma of the Prostate
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Recurrent Prostate Cancer
Stage IIB Prostate Cancer

Interventions: Radiation: brachytherapy
Radiation: image-guided radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2013-05-22

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT01859689

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Phase 3

Withdrawn

Conditions: Stage IIC Melanoma
Stage IB Melanoma
Stage IIB Melanoma
Stage IIA Melanoma

Interventions: Procedure: sentinel lymph node biopsy
Biological: sargramostim
Other: laboratory biomarker analysis
Other: hypertonic saline

First Posted Date: 2013-04-09

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT01826864

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer
Recurrent Renal Cell Cancer

Interventions: Biological: AdGMCAIX-transduced autologous dendritic cells
Biological: therapeutic autologous dendritic cells
Other: laboratory biomarker analysis

First Posted Date: 2013-04-09

Last Posted Date: 2021-08-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT01826877

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

Not Applicable

Completed

Conditions: Glioblastoma
Glioma

Interventions: Radiation: FDOPA PET/CT

First Posted Date: 2013-03-19

Last Posted Date: 2020-07-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 37

Registration Number: NCT01813877

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Squamous Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: Hsp90 inhibitor AUY922
Drug: pemetrexed disodium
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2013-02-06

Last Posted Date: 2020-09-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT01784640

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Phase 1

Completed

Conditions: HER2-positive Breast Cancer
Central Nervous System Metastases
Male Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: lapatinib ditosylate
Drug: everolimus
Drug: capecitabine
Other: laboratory biomarker analysis

First Posted Date: 2013-02-05

Last Posted Date: 2019-11-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT01783756

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy